{"id":627758,"date":"2022-11-29T16:26:01","date_gmt":"2022-11-29T16:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=627758"},"modified":"2022-11-29T16:26:01","modified_gmt":"2022-11-29T16:26:01","slug":"antibodymediated-rejection-market-to-register-incremental-growth-during-the-forecast-period-202232-key-players-bristolmyers-squibb-csl-behring-hansa-biopharma-sanofi-talaris-viela-bio","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/antibodymediated-rejection-market-to-register-incremental-growth-during-the-forecast-period-202232-key-players-bristolmyers-squibb-csl-behring-hansa-biopharma-sanofi-talaris-viela-bio_627758.html","title":{"rendered":"Antibody-mediated Rejection Market to Register Incremental Growth During the Forecast Period (2022-32) | Key Players – Bristol-Myers Squibb, CSL Behring, Hansa Biopharma, Sanofi, Talaris, Viela Bio"},"content":{"rendered":"
\n
\"Antibody-mediated<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Antibody-mediated Rejection Therapeutics Market dynamics are set to evolve in the coming years owing to the launch of emerging therapies, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment. Several key companies are active in the therapeutic domain, and the therapies under development are focused on novel approaches to treat the disease.<\/div>\n

DelveInsight’s “Antibody-mediated Rejection Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Antibody-mediated Rejection market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Antibody-mediated Rejection market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Antibody-mediated<\/p>\n

Antibody-mediated Rejection: An Overview<\/strong><\/p>\n

Antibody-mediated rejection (AMR)—or humoral rejection—after renal transplantation is a devastating event that inevitably leads to allograft loss. AMR poses a significant and continued challenge for long-term graft survival in kidney transplantation. In the continuum of allograft rejection, the development of antibodies plays a critical role, and antibodies are considered a major cause of allograft failure.<\/p>\n

Allograft rejection is a complex process that involves the interplay of different cellular and molecular pathways that cause a broad range of allograft injuries (acute tubular injury, glomerulitis, capillaritis, and fibrinoid necrosis).<\/p>\n

Treatment of AMR is often initiated in situations of diffuse C4d positivity with allograft dysfunction, even in the absence of DSA or histological evidence of AMR. In these cases, the inability to measure DSAs may be related to the presence of non-anti-HLA antibodies, to antigens not present on the single-bead assays, or to the possibility that the DSAs may be completely absorbed into the allograft.<\/em><\/p>\n

Antibody-mediated Rejection Market Key Facts<\/strong><\/p>\n